RE:panobinostat, lomustine, xB3-bevacizumabYes, there is reason to believe that Biodexa will survive. They will have a compelling pipeline.
But they will need to raise a lot of money for clinical and operational purposes.
They can raise money by selling the xB3 platform, which I think may be initial the plan. Biodexa would keep the xBe assets and partnerships existent at the time of this deal's completetion. The buyers of the xB3 platform will get xB3-001 (shelved), xB3-004, progranulin and whatever other xB3 disease/drug combinations that Dr. Deborah Rathjen and her gang foresee, but have not revealed to Bioasis shareholders for "competitive" reasons.
I doubt that private concerns will pay much for the xB3 platform. The LT people have control (75%) of Biodexa. Whatever funding that Biodexa might get for the xB3 platform will run out, soon enough.
And then, with little else to do, Biodexa must do a financing. With a billion shares outstanding it is almost certain that Biodexa will be rolled back and that the Bioasis shareholders will be diluted by a factor of 2, or 4, ending up with 2 or 3% of a Biodexa that no longer owns the xB3 platform.
And that is how Bioasis shareholders will lose almost all of their original investments, and how they will lose the opportunity to ever win what Dr. Deborah Rahjen may be setting herself up to win.
And it's all legal, carefully put together, but there will be no honour in it. They know, however, that lots of money, and the beating of others, assuages a lot of guilt.
They will say, "Well, those Bioasis people, they let it happen, they watched. Hell, they voted for Deborah four times before we finally managed to kill them all off. We won fair and square. Survival of the fittest. Now, what's the next play...?"
jd